Filters

20192

More filters

20212
Reset filters

Settings

End date: 2024 × Start date: 2020 × DDC: 570 × Publisher: Basel : Molecular Diversity Preservation International × WGL Institute: LIKAT ×

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Isoquinolinamine FX-9 Exhibits Anti-Mitotic Activity in Human and Canine Prostate Carcinoma Cell Lines
    (Basel : Molecular Diversity Preservation International, 2019) Schille, Jan Torben; Nolte, Ingo; Packeiser, Eva-Maria; Wiesner, Laura; Hein, Jens Ingo; Weiner, Franziska; Wu, Xiao-Feng; Beller, Matthias; Junghanss, Christian; Escobar, Hugo Murua
    Current therapies are insufficient for metastatic prostate cancer (PCa) in men and dogs. As human castrate-resistant PCa shares several characteristics with the canine disease, comparative evaluation of novel therapeutic agents is of considerable value for both species. Novel isoquinolinamine FX-9 exhibits antiproliferative activity in acute lymphoblastic leukemia cell lines but has not been tested yet on any solid neoplasia type. In this study, FX-9's mediated effects were characterized on two human (PC-3, LNCaP) and two canine (CT1258, 0846) PCa cell lines, as well as benign solid tissue cells. FX-9 significantly inhibited cell viability and induced apoptosis with concentrations in the low micromolar range. Mediated effects were highly comparable between the PCa cell lines of both species, but less pronounced on non-malignant chondrocytes and fibroblasts. Interestingly, FX-9 exposure also leads to the formation and survival of enlarged multinucleated cells through mitotic slippage. Based on the results, FX-9 acts as an anti-mitotic agent with reduced cytotoxic activity in benign cells. The characterization of FX-9-induced effects on PCa cells provides a basis for in vivo studies with the potential of valuable transferable findings to the benefit of men and dogs. © 2019 by the authors. Licensee MDPI, Basel, Switzerland.
  • Thumbnail Image
    Item
    Key Role of Reactive Oxygen Species (ROS) in Indirubin Derivative-Induced Cell Death in Cutaneous T-Cell Lymphoma Cells
    (Basel : Molecular Diversity Preservation International, 2019) Soltan, Marwa Y.; Sumarni, Uly; Assaf, Chalid; Langer, Peter; Reidel, Ulrich; Eberle, Jürgen
    Cutaneous T-cell lymphoma (CTCL) may develop a highly malignant phenotype in its late phase, and patients may profit from innovative therapies. The plant extract indirubin and its chemical derivatives represent new and promising antitumor strategies. This first report on the effects of an indirubin derivative in CTCL cells shows a strong decrease of cell proliferation and cell viability as well as an induction of apoptosis, suggesting indirubin derivatives for therapy of CTCL. As concerning the mode of activity, the indirubin derivative DKP-071 activated the extrinsic apoptosis cascade via caspase-8 and caspase-3 through downregulation of the caspase antagonistic proteins c-FLIP and XIAP. Importantly, a strong increase of reactive oxygen species (ROS) was observed as an immediate early effect in response to DKP-071 treatment. The use of antioxidative pre-treatment proved the decisive role of ROS, which turned out upstream of all other proapoptotic effects monitored. Thus, reactive oxygen species appear as a highly active proapoptotic pathway in CTCL, which may be promising for therapeutic intervention. This pathway can be efficiently activated by an indirubin derivative. © 2019 by the authors. Licensee MDPI, Basel, Switzerland.